Companies
Bristle
an at-home oral-microbiome DNA (shotgun) sequencing test scoring caries, gingivitis/periodontitis and halitosis risk — the diagnostics layer.
- Country
- United States
Commercial
At-home oral microbiome DNA (shotgun) sequencing test; scores caries, gingivitis/periodontitis and halitosis risk — the diagnostics layer of the oral-microbiome category
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaefsanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Total funding of $3.125M, including a $3M seed round in 2022 and $125K pre-seed in 2021 | getlatka.com · bristlehealth.com |
| Headcount | 55 employees as of 2026 | getlatka.com |
| Revenue | $8.3M estimated annual revenue for 2024 | getlatka.com |
| Certification | Tests are analyzed in a CLIA-certified U.S. laboratory | careproviders.bristlehealth.com · bristlehealth.com · tinyhealth.com |
| Production site | 1445 N Loop W, Suite 820, Houston, TX 77008 (Laboratory address) | bristlehealth.com |
Independent sources: getlatka.com · tinyhealth.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Probiotic oral care | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.